Registered title, quoted from ClinicalTrials.gov
Minimal Access Versus Conventional Latissimus Dorsi Flap Harvest for Breast Reconstruction
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Sun Yat-sen Memorial Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06319157, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
18 years to 70 years; sex: women only
Registered eligibility fields
Breast cancer was confirmed by histology or biopsy.
Inclusion criterion 2
Female patients with early-stage breast cancer between the ages of 18 and 70.
Inclusion criterion 1
After neoadjuvant therapy, large monofocal carcinoma (>5 cm) confined to the breast shrunk to <5 cm.
Inclusion criterion 4
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06319157, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Female patients with early-stage breast cancer between the ages of 18 and 70.
- Breast cancer was confirmed by histology or biopsy.
- Breast-conserving surgery or multifocal breast cancer or large unifocal breast cancer (<5cm) can be accepted.
- After neoadjuvant therapy, large monofocal carcinoma (>5 cm) confined to the breast shrunk to <5 cm.
- No chest wall, cutaneous or NAC invasion (including Paget's disease).
- Mild to moderate breast sagging, and the patient has the willingness to undergo autologous reconstruction of the latissimus dorsi.
- There is no need to obtain additional back skins.
- Willing to participate and able to complete follow-up and evaluation during the study.
Exclusion Criteria:
- Patients with advanced breast cancer (stage III and above) or metastatic breast cancer or inflammatory breast cancer.
- The risk of recurrence is expected to be high.
- History of thoracic and dorsal vascular injury.
- Patients with severe heart, lung, or liver disease who cannot withstand surgery and anesthesia.
- Patients with active infection or severe immune system disease.
- Patients with severe allergic reactions to materials related to latissimus dorsi muscle flap transplantation.
- Patients with other major surgeries or reconstructive surgeries planned for the near future.
- Patients with cognitive dysfunction or psychiatric disorders who cannot understand and cooperate with the requirements of the study.
- Patients who refuse to participate in the study or are unable to complete follow-up and evaluation during the study.
Quoted from ClinicalTrials.gov, NCT06319157, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06319157, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.